PRIMARY STUDY

Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents

Key Findings:  Resulting data suggests that the CB2 agonist olorinab reduces visceral hypersensitivity in animal models of colitis. As such, the authors posit that the compound may provide a novel therapy for IBD- and IBS-associated abdominal pain.